Worth reading
63In focus
Scored from 4 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
608
¥100 million (decline in FY2026 revenue versus the current fiscal year)Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFY2025 (fiscal year ending March 2026)8 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales5,158 Hundreds of millions of yen+5.9%
Operating profit¥1,371 100 million +21.7%core operating profit
Ordinary income¥1,383 100 million core profit before tax
Net income¥1,035 100 million +14.5%core profit for the year attributable to owners of the parent
Operating profit margin26.6 % core basis
Selling, general and administrative expenses¥1,236 100 million excluding research and development expenses
Results for the three months of the current quarterQuarterly figures for revenue from major products are provided for April–June, July–September, October–December and January–March. Standalone quarterly figures for consolidated results are Not disclosed
Full-year earnings forecast
Revenue
4,550 Hundreds of millions of yen
Core operating profit
1,240 Hundreds of millions of yen
Core profit for the period
¥930 100 million attributable to owners of the parent
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Domestic product sales¥10.3 billion decline in revenue
- Overseas product sales¥22.1 billion increase in revenue
- Royalties and other¥17.1 billion increase in revenue
- Core operating profit¥24.5 billion increase in profit
- Research and development costs¥1.8 billion increase
- Selling, general and administrative expenses (excluding R&D expenses)¥1.4 billion increase
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Research and development investment is expected to remain above 30% of revenueNew initiatives
- Continuation of active research and development investment, including global trials for sapablursen and ONO-4578
- Progress in the development pipeline, including the submission of a U.S. approval application for ONO-4059 and the start of a Phase I trial for ONO-7429 in Japan
Key KPIsA metric the company considers important as a management benchmark.
- Domestic product sales2,814 Hundreds of millions of yenYear on year against the same period last year3.5% decline
- Overseas product sales612 Hundreds of millions of yenYear on year against the same period last year56.5% increase
- Royalties and other1,732 Hundreds of millions of yenYear on year against the same period last yearUp 10.9%
- Product and merchandise sales3,426 Hundreds of millions of yen
- Royalty income (Opdivo)1,223 Hundreds of millions of yenYear on year against the same period last year¥113 billion in the previous fiscal year
- Royalty income (Keytruda)295 Hundreds of millions of yenYear on year against the same period last year¥26.4 billion in the previous fiscal year
Segment results
The Pharmaceutical Business is the sole operating segment. Individual breakdowns of revenue and profit by segment are Not disclosedNumber of employees
Number of Employees4,206 People as of the end of March 2026
Change during the period81-person decrease from the end of the previous fiscal year
Capital expenditures
¥550 100 million FY2025: ¥7.9 billion in property, plant and equipment and ¥47.1 billion in intangible assets
Acquisition of treasury shares
The Company reports holding 20,387 thousand treasury shares. The acquisition limit and acquisition period are Not disclosed| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | FY2025 (fiscal year ending March 2026) |
| Net Sales | 5,158 Hundreds of millions of yen (YoY +5.9%) |
| Operating profit | ¥1,371 100 million (core operating profit) (YoY +21.7%) |
| Ordinary income | ¥1,383 100 million (core profit before tax) |
| Net income | ¥1,035 100 million (core profit for the year attributable to owners of the parent) (YoY +14.5%) |
| Operating profit margin | 26.6 % (core basis) |
| Selling, general and administrative expenses | ¥1,236 100 million (excluding research and development expenses) |
| Results for the three months of the current quarter | Quarterly figures for revenue from major products are provided for April–June, July–September, October–December and January–March. Standalone quarterly figures for consolidated results are Not disclosed |
| Full-year earnings forecast | Revenue 4,550 Hundreds of millions of yen / Core operating profit 1,240 Hundreds of millions of yen / Core profit for the period ¥930 100 million (attributable to owners of the parent) |
| Segment results | The Pharmaceutical Business is the sole operating segment. Individual breakdowns of revenue and profit by segment are Not disclosed |
| Breakdown of Factors Affecting the Change | Factors Domestic product sales / Amount ¥10.3 billion decline in revenue, Factors Overseas product sales / Amount ¥22.1 billion increase in revenue, Factors Royalties and other / Amount ¥17.1 billion increase in revenue, Factors Core operating profit / Amount ¥24.5 billion increase in profit, Factors Research and development costs / Amount ¥1.8 billion increase, Factors Selling, general and administrative expenses (excluding R&D expenses) / Amount ¥1.4 billion increase |
| Key KPIs | Indicator name Domestic product sales / Value 2,814 Hundreds of millions of yen / Year on year against the same period last year 3.5% decline, Indicator name Overseas product sales / Value 612 Hundreds of millions of yen / Year on year against the same period last year 56.5% increase, Indicator name Royalties and other / Value 1,732 Hundreds of millions of yen / Year on year against the same period last year Up 10.9%, Indicator name Product and merchandise sales / Value 3,426 Hundreds of millions of yen / Year on year against the same period last year Not disclosed, Indicator name Royalty income (Opdivo) / Value 1,223 Hundreds of millions of yen / Year on year against the same period last year ¥113 billion in the previous fiscal year, Indicator name Royalty income (Keytruda) / Value 295 Hundreds of millions of yen / Year on year against the same period last year ¥26.4 billion in the previous fiscal year |
| Number of employees | Number of Employees 4,206 People (as of the end of March 2026) / Change during the period 81-person decrease from the end of the previous fiscal year |
| Assumptions Underlying the Business Outlook | Research and development investment is expected to remain above 30% of revenue |
| Acquisition of treasury shares | The Company reports holding 20,387 thousand treasury shares. The acquisition limit and acquisition period are Not disclosed |
| Capital expenditures | ¥550 100 million (FY2025: ¥7.9 billion in property, plant and equipment and ¥47.1 billion in intangible assets) |
| New initiatives | Continuation of active research and development investment, including global trials for sapablursen and ONO-4578, Progress in the development pipeline, including the submission of a U.S. approval application for ONO-4059 and the start of a Phase I trial for ONO-7429 in Japan |
Items this document does not state (13)
Gross Profit MarginProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In FY2025, revenue and profit increased due to higher overseas product sales, including products from Deciphera Pharmaceuticals, and higher royalty income. For FY2026, the Company forecasts lower revenue and profit, mainly because the end of the co-promotion agreement for Farxiga with AstraZeneca is expected to reduce product sales and co-promotion expenses.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.